Joseph Catanzaro
Stock Analyst at Piper Sandler
(3.70)
# 786
Out of 5,124 analysts
103
Total ratings
43.18%
Success rate
10.63%
Average return
Main Sectors:
Stocks Rated by Joseph Catanzaro
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NRIX Nurix Therapeutics | Maintains: Overweight | $32 → $35 | $16.85 | +107.72% | 5 | Jan 29, 2026 | |
| IBRX ImmunityBio | Maintains: Overweight | $5 → $7 | $6.05 | +15.70% | 6 | Jan 20, 2026 | |
| CTMX CytomX Therapeutics | Maintains: Overweight | $6.5 → $10 | $5.67 | +76.37% | 6 | Jan 20, 2026 | |
| RVMD Revolution Medicines | Maintains: Outperform | $90 → $143 | $97.49 | +46.68% | 4 | Jan 13, 2026 | |
| AVTX Avalo Therapeutics | Initiates: Outperform | $39 | $14.19 | +174.84% | 1 | Dec 18, 2025 | |
| UPB Upstream Bio | Initiates: Outperform | $51 | $26.20 | +94.66% | 1 | Dec 18, 2025 | |
| BCAX Bicara Therapeutics | Initiates: Neutral | $18 | $15.36 | +17.19% | 1 | Dec 18, 2025 | |
| SYRE Spyre Therapeutics | Initiates: Outperform | $53 | $35.12 | +50.91% | 1 | Dec 18, 2025 | |
| KYMR Kymera Therapeutics | Maintains: Outperform | $81 → $120 | $79.59 | +50.77% | 2 | Dec 11, 2025 | |
| CLDX Celldex Therapeutics | Initiates: Outperform | $48 | $23.83 | +101.43% | 1 | Oct 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $105 | $62.24 | +68.70% | 1 | Oct 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $7.5 → $6 | $2.53 | +137.15% | 10 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $45 | $13.49 | +233.58% | 3 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $105 → $110 | $152.50 | -27.87% | 5 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $37 → $38 | $43.90 | -13.44% | 4 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $15 | $17.60 | -14.77% | 3 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $52 → $53 | $81.23 | -34.75% | 9 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $7 → $10 | $1.60 | +525.00% | 4 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 → $19 | $1.22 | +1,457.38% | 5 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $19 | $9.63 | +97.30% | 1 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $15 | $2.26 | +565.19% | 3 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $36 | $14.22 | +153.16% | 2 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 | $11.41 | +250.57% | 5 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 | $9.16 | +63.76% | 4 | Jun 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $4.5 | $2.28 | +97.37% | 1 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $30 | $1.67 | +1,696.41% | 2 | Apr 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $1.16 | +1,624.14% | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $18 | $12.51 | +43.88% | 1 | Feb 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $1.75 | $2.19 | -20.09% | 2 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $20 | $24.44 | -18.17% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $1.5 | $2.47 | -39.27% | 1 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $240 → $200 | $8.86 | +2,157.34% | 2 | Mar 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $10.74 | +225.88% | 1 | Jun 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $60 | $1.65 | +3,536.36% | 1 | Mar 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $18 | $2.37 | +659.49% | 3 | Apr 7, 2020 |
Nurix Therapeutics
Jan 29, 2026
Maintains: Overweight
Price Target: $32 → $35
Current: $16.85
Upside: +107.72%
ImmunityBio
Jan 20, 2026
Maintains: Overweight
Price Target: $5 → $7
Current: $6.05
Upside: +15.70%
CytomX Therapeutics
Jan 20, 2026
Maintains: Overweight
Price Target: $6.5 → $10
Current: $5.67
Upside: +76.37%
Revolution Medicines
Jan 13, 2026
Maintains: Outperform
Price Target: $90 → $143
Current: $97.49
Upside: +46.68%
Avalo Therapeutics
Dec 18, 2025
Initiates: Outperform
Price Target: $39
Current: $14.19
Upside: +174.84%
Upstream Bio
Dec 18, 2025
Initiates: Outperform
Price Target: $51
Current: $26.20
Upside: +94.66%
Bicara Therapeutics
Dec 18, 2025
Initiates: Neutral
Price Target: $18
Current: $15.36
Upside: +17.19%
Spyre Therapeutics
Dec 18, 2025
Initiates: Outperform
Price Target: $53
Current: $35.12
Upside: +50.91%
Kymera Therapeutics
Dec 11, 2025
Maintains: Outperform
Price Target: $81 → $120
Current: $79.59
Upside: +50.77%
Celldex Therapeutics
Oct 21, 2025
Initiates: Outperform
Price Target: $48
Current: $23.83
Upside: +101.43%
Oct 21, 2025
Initiates: Outperform
Price Target: $105
Current: $62.24
Upside: +68.70%
Feb 28, 2025
Maintains: Neutral
Price Target: $7.5 → $6
Current: $2.53
Upside: +137.15%
Feb 27, 2025
Maintains: Overweight
Price Target: $50 → $45
Current: $13.49
Upside: +233.58%
Feb 12, 2025
Maintains: Overweight
Price Target: $105 → $110
Current: $152.50
Upside: -27.87%
Feb 12, 2025
Maintains: Overweight
Price Target: $37 → $38
Current: $43.90
Upside: -13.44%
Jan 17, 2025
Maintains: Overweight
Price Target: $40 → $15
Current: $17.60
Upside: -14.77%
Jan 10, 2025
Maintains: Neutral
Price Target: $52 → $53
Current: $81.23
Upside: -34.75%
Dec 13, 2024
Maintains: Overweight
Price Target: $7 → $10
Current: $1.60
Upside: +525.00%
Oct 31, 2024
Maintains: Overweight
Price Target: $10 → $19
Current: $1.22
Upside: +1,457.38%
Oct 7, 2024
Initiates: Overweight
Price Target: $19
Current: $9.63
Upside: +97.30%
Sep 23, 2024
Maintains: Overweight
Price Target: $12 → $15
Current: $2.26
Upside: +565.19%
Aug 15, 2024
Maintains: Overweight
Price Target: $36
Current: $14.22
Upside: +153.16%
Jul 8, 2024
Maintains: Overweight
Price Target: $40
Current: $11.41
Upside: +250.57%
Jun 14, 2024
Maintains: Overweight
Price Target: $15
Current: $9.16
Upside: +63.76%
May 16, 2024
Initiates: Overweight
Price Target: $4.5
Current: $2.28
Upside: +97.37%
Apr 25, 2024
Maintains: Overweight
Price Target: $26 → $30
Current: $1.67
Upside: +1,696.41%
Apr 22, 2024
Initiates: Overweight
Price Target: $20
Current: $1.16
Upside: +1,624.14%
Feb 12, 2024
Initiates: Overweight
Price Target: $18
Current: $12.51
Upside: +43.88%
May 23, 2023
Downgrades: Neutral
Price Target: $15 → $1.75
Current: $2.19
Upside: -20.09%
Dec 20, 2022
Maintains: Overweight
Price Target: $18 → $20
Current: $24.44
Upside: -18.17%
May 5, 2022
Downgrades: Neutral
Price Target: $25 → $1.5
Current: $2.47
Upside: -39.27%
Mar 10, 2022
Maintains: Overweight
Price Target: $240 → $200
Current: $8.86
Upside: +2,157.34%
Jun 21, 2021
Initiates: Overweight
Price Target: $35
Current: $10.74
Upside: +225.88%
Mar 25, 2021
Initiates: Overweight
Price Target: $60
Current: $1.65
Upside: +3,536.36%
Apr 7, 2020
Maintains: Overweight
Price Target: $28 → $18
Current: $2.37
Upside: +659.49%